Proteomics International Restructures with $1 Million Cost Savings and Board Changes

Significant Job Cuts Reflect Commercial Focus

Proteomics International Laboratories (ASX:PIQ) has initiated a sweeping organisational restructure that will see nine roles, roughly 25% of its workforce, made redundant. The move is designed to improve operational efficiency and align the company more closely with its evolving commercial priorities. Expected annualised cost savings exceed $1 million, bolstering the company’s cash position and funding key commercial initiatives.

This restructuring is a clear pivot away from the company’s historically research-driven model towards a commercially focused diagnostics business. CEO David Morris emphasised the necessity of these tough decisions to streamline operations and sharpen execution discipline as Proteomics International advances its commercialisation strategy.

Dual CFO and Company Secretary Role Strengthens Financial Governance

In tandem with the restructure, Proteomics International has appointed Tim Luscombe as Chief Financial Officer while he continues as Company Secretary. Luscombe brings extensive experience supporting Australian life sciences and medical technology firms, including his role as a director at Bio101, a firm specialising in outsourced CFO and governance services.

This dual appointment aims to enhance financial governance and reporting efficiency during the company’s transition phase. Luscombe’s background in financial strategy and ASX compliance positions him well to navigate the complexities of a life sciences company moving towards commercialisation.

Board Changes Mark End of an Era

Long-serving board member Neville Gardiner has retired effective 17 April 2026. Gardiner, who served as Chairman and guided the company through its formative research-led growth phase, was acknowledged by Chairman Dr James Williams for his leadership and commitment during a critical transition period. Gardiner’s departure signals a generational shift as the board adapts to new commercial imperatives.

Strategic Review to Unfold with Financial Update

The company has indicated that further details of its strategic review will be released alongside the forthcoming Appendix 4C. This upcoming disclosure will be closely watched for insights into how the restructure and leadership changes will impact Proteomics International’s financial trajectory and commercial rollout plans.

Proteomics International’s recent efforts to secure international patents and regulatory accreditations, such as the Canadian patent for its PromarkerEso test, highlight its ambition to scale its diagnostic technology globally. This restructuring appears to be a foundational step to support those ambitions with a leaner, more commercially driven organisation, building on the leadership changes with CEO David Morris earlier this year to accelerate Promarker® growth.